Vyndaqel (tafamidis)

pCPA File Number: 21922
Negotiation Status:
Concluded with an LOI
Indication(s):
Cardiomyopathy due to transthyretin-mediated amyloidosis
Sponsor/Manufacturer:
Pfizer Canada ULC
CDA-AMC Project Number:
SF0722-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: